Treatment of Osteopathology of the Jaws Associated with Bone Resorption Inhibitors: An 8-Year Single-Centre ExperienceJacobsen C1*,Zemann W1, Obwegeser JA1, Seifert B2, Gratz KW1 and Metzler P1
- *Corresponding Author:
- Dr. Jacobsen C, M.D
D.M.D, Department of Craniomaxillofacial Surgery
University Hospital of Zurich, Switzerland
Fax: +4144255 8989
E-mail: [email protected]
Received date : August 10, 2012; Accepted date : October 18, 2012; Published date : October 20, 2012
Citation: Jacobsen C, Zemann W, Obwegeser JA, Seifert B, Gratz KW, et al. (2012) Treatment of Osteopathology of the Jaws Associated with Bone Resorption Inhibitors: An 8-Year Single-Centre Experience. Dentistry 2:146. doi:10.4172/2161-1122.1000146
Copyright: © 2012 Jacobsen C, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Since the discovery that treatment with oral or intravenous bisphosphonate causes bisphosphonate-related osteonecrosis of the jaws (BRONJ), numerous articles on this disease have been published. The number of causative agents was extended after intervention of RANKL-inhibitor denosumab, which has been shown to be as well associated with osteopathology of the jaws. Nonetheless, knowledge of the specific pathogenesis of this clinical entity remains lacking, and no standardized treatment protocols are available. Therefore, despite the vast literature on osteonecrosis of the jaws, there is still considerable ambiguity regarding the optimum treatment of this disease, especially among general practitioners who deal increasingly with bisphosphonates.